Epithalon

The evidence base does not support the healthspan claims made for it. A 2025 review in the International Journal of Molecular Sciences (Araj et al.) covers roughly 25 years of in vitro, in vivo and in silico work and concludes the mechanism is still uncertain, noting that physico-chemical and structural investigation of the peptide remains limited. Cell-culture work (Khavinson 2003, with a 2025 replication) shows telomerase upregulation and telomere elongation in human fibroblast lines, but telomerase activity did not track telomere length consistently, so even the in-vitro mechanism is unsettled. Animal work reports median and maximum lifespan increases in the region of 12 to 24 percent. What it does NOT show: there is no randomised, placebo-controlled human trial of Epithalon for any longevity or healthspan outcome. The frequently cited human mortality dataset (n=266) was neither randomised nor placebo-controlled and was conducted and reported by the same group that developed the peptide, and no independent group has replicated it under controlled conditions. Nearly all human data originates from a single Russian laboratory and the Soviet-era and Russian pineal-peptide literature. Commercial availability and clinic marketing are far ahead of the evidence. Note also that surface-level web results for this compound are heavily contaminated by peptide-vendor SEO pages that assert confident legal and clinical claims without sourcing, and these should not be treated as evidence.

What it is

Plain-language explainer

Categories

Common questions

What is Epithalon?

The evidence base does not support the healthspan claims made for it. A 2025 review in the International Journal of Molecular Sciences (Araj et al.) covers roughly 25 years of in vitro, in vivo and in silico work and concludes the mechanism is still uncertain, noting that physico-chemical and structural investigation of the peptide remains limited. Cell-culture work (Khavinson 2003, with a 2025 replication) shows telomerase upregulation and telomere elongation in human fibroblast lines, but telomerase activity did not track telomere length consistently, so even the in-vitro mechanism is unsettled. Animal work reports median and maximum lifespan increases in the region of 12 to 24 percent. What it does NOT show: there is no randomised, placebo-controlled human trial of Epithalon for any longevity or healthspan outcome. The frequently cited human mortality dataset (n=266) was neither randomised nor placebo-controlled and was conducted and reported by the same group that developed the peptide, and no independent group has replicated it under controlled conditions. Nearly all human data originates from a single Russian laboratory and the Soviet-era and Russian pineal-peptide literature. Commercial availability and clinic marketing are far ahead of the evidence. Note also that surface-level web results for this compound are heavily contaminated by peptide-vendor SEO pages that assert confident legal and clinical claims without sourcing, and these should not be treated as evidence.

How strong is the evidence for Epithalon?

Commercial. It is offered and sold, which is a statement about availability, not about efficacy.

Is Epithalon approved in Singapore?

variis has no Health Sciences Authority position on file for Epithalon. Absence of a recorded position is not approval.

Is Epithalon approved in Australia?

variis has no Therapeutic Goods Administration position on file for Epithalon. Absence of a recorded position is not approval.

What else is Epithalon called?

Also known as Epitalon, Epithalamin, AEDG peptide, Ala-Glu-Asp-Gly.